Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
CHRS Price Targets and Analyst Ratings NASDAQ:CHRS
Historical Ratings and Targets
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-06-14 | -3.31% | UBS | $7.00 | Initiates Coverage On | Neutral |
| 2022-05-20 | 245.3% | Mizuho | $30.00 $25.00 | Maintains | Buy |
| 2022-05-09 | 107.18% | Barclays | $20.00 $15.00 | Maintains | Overweight |
| 2022-03-07 | 107.18% | JP Morgan | $15.00 | Downgrades | Overweight Neutral |
| 2021-11-09 | 314.36% | HC Wainwright & Co. | $36.00 $30.00 | Maintains | Buy |
| 2021-07-23 | 397.24% | HC Wainwright & Co. | $26.00 $36.00 | Maintains | Buy |
| 2021-05-17 | 231.49% | Barclays | $28.00 $24.00 | Maintains | Overweight |
| 2021-05-07 | 259.12% | HC Wainwright & Co. | $29.00 $26.00 | Maintains | Buy |
| 2021-02-25 | 300.55% | HC Wainwright & Co. | $33.00 $29.00 | Maintains | Buy |
| 2020-11-19 | 314.36% | Mizuho | $35.00 $30.00 | Maintains | Buy |
| 2020-11-06 | 341.99% | HC Wainwright & Co. | $33.00 $32.00 | Maintains | Buy |
| 2020-08-10 | 314.36% | Truist Securities | $26.00 $30.00 | Maintains | Buy |
| 2020-08-07 | 355.8% | HC Wainwright & Co. | $30.00 $33.00 | Maintains | Buy |
| 2020-07-16 | 176.24% | B of A Securities | $20.00 | Initiates Coverage On | Neutral |
| 2020-04-17 | 259.12% | SunTrust Robinson Humphrey | $26.00 | Initiates Coverage On | Buy |
| 2020-02-28 | 314.36% | HC Wainwright & Co. | $29.00 $30.00 | Reiterates | Buy |
| 2020-02-06 | 383.43% | JP Morgan | $33.00 $35.00 | Maintains | Overweight |
| 2019-11-07 | 328.18% | Citigroup | $27.00 $31.00 | Maintains | Buy |
| 2019-08-13 | 493.92% | Mizuho | $43.00 | Initiates Coverage On | Buy |
| 2019-06-11 | 314.36% | Barclays | $30.00 | Initiates Coverage On | Overweight |
CHRS Stock Trend
The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $7.33 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.
Given the current short-term trend, the stock is expected to fall -45.58% during the next 3 months and, with a 90% probability hold a price between $2.70 and $3.99 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-07-05 | $4.87 | $6.05 | $7.23 |
| 2022-07-06 | $4.77 | $5.95 | $7.13 |
| 2022-07-07 | $4.67 | $5.85 | $7.04 |
| 2022-07-08 | $4.57 | $5.75 | $6.94 |
| 2022-07-11 | $4.47 | $5.66 | $6.84 |
| 2022-07-12 | $4.37 | $5.56 | $6.74 |
| 2022-07-13 | $4.28 | $5.46 | $6.64 |
| 2022-07-14 | $4.18 | $5.36 | $6.54 |
| 2022-07-15 | $4.08 | $5.26 | $6.44 |
| 2022-07-18 | $3.98 | $5.16 | $6.34 |
| 2022-07-19 | $3.88 | $5.06 | $6.24 |
| 2022-07-20 | $3.78 | $4.96 | $6.14 |
| 2022-07-21 | $3.68 | $4.86 | $6.05 |
| 2022-07-22 | $3.58 | $4.76 | $5.95 |
| 2022-07-25 | $3.48 | $4.67 | $5.85 |
| 2022-07-26 | $3.38 | $4.57 | $5.75 |
| 2022-07-27 | $3.28 | $4.47 | $5.65 |
| 2022-07-28 | $3.19 | $4.37 | $5.55 |
| 2022-07-29 | $3.09 | $4.27 | $5.45 |
| 2022-08-01 | $2.99 | $4.17 | $5.35 |
| 2022-08-02 | $2.89 | $4.07 | $5.25 |
| 2022-08-03 | $2.79 | $3.97 | $5.15 |
| 2022-08-04 | $2.69 | $3.87 | $5.05 |
| 2022-08-05 | $2.59 | $3.77 | $4.96 |
| 2022-08-08 | $2.49 | $3.67 | $4.86 |
| 2022-08-09 | $2.39 | $3.58 | $4.76 |
| 2022-08-10 | $2.29 | $3.48 | $4.66 |
| 2022-08-11 | $2.20 | $3.38 | $4.56 |
| 2022-08-12 | $2.10 | $3.28 | $4.46 |
| 2022-08-15 | $2.00 | $3.18 | $4.36 |
Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companys product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid ar... ![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
